Cell and Gene Therapy Catapult’s Post

Did you know that all of our webinar recordings can be accessed for free on our website? ➡️ https://buff.ly/3uE5HLS Head over to our webinar recordings page to learn more about #cell and #gene therapies, the current #challenges associated with their development, UK patient referral pathways, how to develop a robust #TPP and much more... Tune in ☝️ #GeneTherapy #CellTherapy #ATMPs #Innovation

Today's the day! Our webinar in partnership with Charles River Laboratories will explore the expanding role of bioanalysis in AAV therapies, focusing on biodistribution, transgene expression, immunogenicity and ELISpot.  Find out more >>> https://hubs.ly/Q02WvzH20

Analytics within Cell and Gene Therapy manufacturing are so critical given the complexity of the medicines being created. However they do at times present obstacles, whether that be in the form of turn around times to obtain critical results, or the burden on samples required to obtain a viable result. To further explore this we have created the attached survey and urge anyone who works in the field and has experience with analytics to provide your feedback. The survey will take less than 10 minutes and will help guide on our strategy for building out collaborations and consortiums to address the problems we identify.

Calling experts from across the #AdvancedTherapy field to help us guide a strategy in simplifying analytics 📣 ➡️ https://ow.ly/k00k50U5170 The #cell and #gene therapy industry faces significant barriers to growth due to inconsistent and fragmented analytical platforms, and we are looking to pull together a consortium to overcome these barriers. To support this, we have developed a survey to gather insights from industry experts on the specific challenges encountered with current analytical methods. Complete the survey ☝️ Survey deadline 🚨: 18th December #CellTherapy #GeneTherapy #AdvancedTherapies #ATMPs

Get involved share the love / pain / thoughts Let’s make CGT analytics better

Are you a #cell or #gene therapy developer looking for support to develop a robust target product profile (TPP) and maximise the probability of successful therapy adoption? Take a look at our TPP guide which outlines each of the attributes included in a TPP in detail, to help therapy developers navigate the process and support the development of commercially viable products. Learn more: https://lnkd.in/dthc5DeN #CellTherapy #GeneTherapy #AdvancedTherapies #ATMPs

Developing a Target Product Profile (TPP) very early on in ATMP development is crucial to ensure that your therapeutic product is designed to meet its intended use and regulatory requirements, increasing the likelihood of producing a safe, effective, and marketable product. Look at your TPP as a strategic document that serves as a common vision across various stakeholders, including regulatory agencies, investors, development and clinical teams, healthcare providers, and so on. It ensures that everyone has a clear understanding of the product’s goals and requirements, allowing for efforts and resources to be focused where needed.

Pharmacogenomics (PGx) is gaining momentum and will have increasing applicability to long-term care, writes Robert Accetta, RPh, BCGP, FASCP.   "Newly approved medications are now targeting receptors related to gene anomalies, and first- and second-generation legacy medications are being re-evaluated. Practice guidelines for drug–gene therapy recommendations are now available, curated, and disseminated by government-sponsored partners. "For those inquiring about PGx, the questions include how and why to implement this additional strategy into practice."   Read more in our April 2024 issue https://lnkd.in/eSTynFUn 📸: thanapipat kulmuangdoan

One example is how GTC's Hematology Profile Plus and Liquid Trace Hematology can detect AML with KMT2A-PTD. KMT2A partial tandem duplication that spans exons 2 through 8-10, which we are able to identify by evaluating copy number variation over the whole length of the gene. Learn more: https://lnkd.in/dWGyJYW6 #RNA #KMT2A #CNV

One example is how GTC's Hematology Profile Plus and Liquid Trace Hematology can detect AML with KMT2A-PTD. KMT2A partial tandem duplication that spans exons 2 through 8-10, which we are able to identify by evaluating copy number variation over the whole length of the gene. Learn more: https://lnkd.in/dWGyJYW6 #RNA #KMT2A #CNV